Introduction {#s1}
============

Stroke is one of the leading causes of death and the most common cause of serious long-term disability in adults worldwide (Liu et al., [@B31]; Writing Group Members et al., [@B47]). As the most common type of stroke, ischemic stroke (IS) accounts for over 85% of all strokes (van der Worp and van Gijn, [@B44]). Currently, the only approved treatments for acute ischemic stroke (AIS) are intravenous thrombolysis with intravenous tissue plasminogen activator (t-PA) within 3--4.5 h after symptom onset and mechanical thrombectomy (Berkhemer et al., [@B4]; Derex and Cho, [@B14]). However, the narrow 3--4.5 h therapeutic time window for rt-PA thrombolysis urges researchers to seek new treatment strategies and medicines. Although substantial progress has been made in fully understanding the pathomechanism of neuronal death caused by stroke in recent years, clinical methods to effectively reverse neuronal damage caused by ischemia are still lacking. Therefore, further understanding the pathophysiological mechanism of the development and recovery of AIS might provide a new and more effective way to improve outcomes after AIS.

According to the human Encyclopedia of DNA Elements (ENCODE) project, approximately 80% of the Homo sapien genome is transcribed as nonprotein-coding RNAs (ncRNAs; ENCODE Project Consortium, [@B12]). Generally, ncRNAs, including long noncoding RNAs (lncRNAs) and microRNAs, are abundantly expressed in the human central nervous system and are implicated in several neurological diseases (Cao et al., [@B7]; Qureshi et al., [@B37]). LncRNAs represent a class of transcripts longer than 200 nucleotides in length that lack protein-coding capability and are considered "junk" DNA. However, with the rapid development of RNA sequencing (RNA-Seq) technology, current studies have demonstrated that lncRNAs play a pivotal role in regulating gene expression (Martianov et al., [@B32]) and are involved in many critical biological processes, such as differentiation, organogenesis, apoptosis, genomic imprinting, regulation of mRNA splicing and translational control (Mercer et al., [@B33]; Geisler and Coller, [@B18]; Ulitsky and Bartel, [@B43]). In recent years, numerous researchers have shown great interest in exploring the association between lncRNA profiles and neurological disorders (Wu et al., [@B48]; Dykstra-Aiello et al., [@B17]; He et al., [@B23]). Importantly, an increasing number of studies have shown that lncRNAs play crucial roles in the pathogenesis of IS (Dykstra-Aiello et al., [@B17]; Liu et al., [@B30]). Although the functions of most lncRNAs in neuroprotection and IS remain to be clarified (Dharap et al., [@B15]), RNA-Seq analyses have indicated that the abnormal expression of lncRNAs is closely associated with IS, and increasing evidence has confirmed that lncRNAs generally contribute to the development and progression of IS as well as to recovery from IS (Bhattarai et al., [@B5]; Guo et al., [@B20]; Wang et al., [@B45]; Zhang et al., [@B51]; Liu et al., [@B30]).

Currently, the functional study of lncRNAs is mainly focused on animal models of IS. As distinct differences exist between animals and humans, the lncRNA profiles in AIS definitely need to be further investigated, especially among different races. Moreover, current research on this issue has focused on only a small number of lncRNAs, such as MIAT, GAS5, MALAT1, SNHG1 and ANRIL (Guo et al., [@B20]; Chen et al., [@B10]; Zhang et al., [@B51]; Zhu et al., [@B53]; Liu et al., [@B30]). Many lncRNAs have not yet been discovered in patients with AIS; more importantly, the functions of most lncRNAs have not yet been clarified (Kopp and Mendell, [@B26]). Therefore, we aim to use the RNA-Seq technique to generate an expression profile of lncRNAs and mRNAs related to AIS from the circulating blood of Southern Chinese Han patients and elaborate the potential function of lncRNAs *via* interactions with specific mRNAs.

To the best of our knowledge, this is the first study to investigate the lncRNA expression profile in AIS in the South Chinese Han population. In the present study, the lncRNA expression profile in the circulating blood of patients with AIS was investigated by using RNA-Seq analysis, and the results were validated with real-time polymerase chain reaction (RT-PCR). Moreover, bioinformatics analyses were further applied to predict the functions of differentially expressed lncRNAs. Furthermore, the effects and potential underlying molecular mechanisms of lncRNAs on the pathological process of AIS were elaborated through interactions with specific mRNAs. These findings will help illustrate the molecular pathological mechanism of AIS and identify new biomarkers and therapeutic targets for AIS in the future.

Materials and Methods {#s2}
=====================

Study Subjects {#s2-1}
--------------

This study was approved by the Ethical Committee of The First Affiliated Hospital of Guangxi Medical University (no. 2018-KY-E-063). Thirty-two patients who received a clinical diagnosis of AIS involving large vessel occlusion of the anterior circulation between September 2018 and June 2019 were selected for inclusion in this study. Thirty-two healthy controls from the Physical Examination Center of The First Affiliated Hospital of Guangxi Medical University from September 2018 to November 2018 were also included. Three AIS samples and three control samples were randomly selected from 32 patients and 32 healthy controls for RNA-seq, and all the samples were used for the validation of differentially expressed lncRNAs. Written consent forms were obtained from all participants or their next of kin before sample collection. The inclusion criteria for patients with AIS were as follows: (1) patients were men and women aged 50 and over; (2) patients were of Southern Chinese Han ethnicity; (3) patients had available blood samples; (4) AIS was confirmed by brain imaging (CT/MRI); (5) IS was caused by large artery occlusion occurring in the anterior circulation; (6) patients did not undergo recanalization therapy; (7) patients had regular physical examinations; (8) patients had no history of cardiovascular or cerebrovascular diseases; and (9) patients had no history of severe lung, liver, kidney or other systemic diseases.

Patients with AIS were excluded if they met any of the following qualifications: (1) they had cerebral hemorrhage confirmed by skull CT; (2) they underwent endovascular intervention therapy; (3) they had severe liver or kidney dysfunction; (4) they required diuretics; (5) they had a history of stroke; (6) they had autoimmune disorders or hematological diseases; (7) they had brain tumors or other forms of cancer; and (8) they participated in an ongoing clinical trial study. Healthy controls with a history of cardiovascular or cerebrovascular disorders, hematologic disease, recent infection or other medical illnesses were excluded.

The historical assessments and physical examinations for all the included participants were performed by a neurology resident. The categories of stroke etiologies were assessed using the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria (Adams et al., [@B1]) and classified as large vessel atherosclerosis, small vessel occlusion, cardioembolism, stroke with determined etiology or stroke with undetermined etiology. Patients with large vessel atherosclerotic stroke were included in this study. The classifications of IS subtypes according to the Oxfordshire Community Stroke Project (OCSP) criteria (Bamford et al., [@B2]) were as follows: total anterior circulation infarct (TACI), partial anterior circulation infarct (PACI), posterior circulation infarct (POCI), and lacunar infarct (LACI).

Demographic and clinical information, including age, sex, hypertension, hyperlipidemia, diabetes mellitus and homocysteine, were collected.

Sample Collection and Total RNA Extraction {#s2-2}
------------------------------------------

Circulating blood samples were collected in sterile evacuated tubes containing EDTA by venipuncture on the day of admission or the next day and processed immediately or within a few hours. Total RNA was extracted from the circulating blood of AIS patients and healthy controls using TRIzol reagent (Life Technologies, Franklin, MA, USA) according to the manufacturer's instructions. Then, the RNA concentration and purity were analyzed by a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). RNA contamination and degradation were assessed by electrophoresis on 1% agarose gels. RNA integrity and quality were evaluated by an Agilent 2100 Bioanalyzer (Agilent Technologies, La Jolla, CA, USA). All total RNA samples were stored at −80°C until further analysis.

Construction of RNA-Seq Libraries {#s2-3}
---------------------------------

Transcriptome sequencing was performed by Beijing Novogene Bioinformatics Technology Co., Limited (Beijing, China[^1^](#fn0001){ref-type="fn"}). RNA-Seq libraries were generated according to the manufacturer's protocols using the NEB Next Ultra Directional RNA Library Prep Kit for Illumina (Illumina, CA, USA). The gene expression profiles of the AIS and healthy control groups were investigated using Illumina HiSeq™ 2500 Sequencing according to the manufacturer's guide (Illumina, CA, USA). The raw data were normalized. Clean reads were obtained from the raw data by discarding adapter and poly-N sequences and reads of low quality. All further downstream analyses were based on the high-quality clean data. Altered lncRNAs and mRNAs with statistically significant differences between healthy controls and patients with AIS were determined by *P*-value, false discovery rate (FDR) and fold-change filtering. Transcripts with a *P*-value of ≤0.05 and threshold values of ≥2-fold change were specified as differentially expressed transcripts.

GO and KEGG Pathway Analyses {#s2-4}
----------------------------

GO enrichment analysis was performed to annotate the functions of the differentially expressed mRNAs and lncRNAs with GO terms. GO enrichment analysis describes the characteristics of altered genes from three structured networks of terms: biological processes, cellular components and molecular functions. The abnormal expression of mRNAs between AIS patients and healthy controls was included in GO enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses according to the latest KEGG database. The above analysis enabled us to determine the biological pathways of the altered mRNAs in the acquired samples.

LncRNA-mRNA Coexpression Analysis {#s2-5}
---------------------------------

LncRNA-mRNA networks were constructed according to the correlation analysis of differentially expressed mRNAs and lncRNAs. For each mRNA-lncRNA pair, the Pearson correlation was calculated, and significantly correlated pairs with a Pearson correlation coefficient value over 0.98 were selected to construct the network using Cytoscape 3.5.1[^2^](#fn0002){ref-type="fn"}. We mainly selected genes potentially related to IS to construct the lncRNA-mRNA networks.

Construction and Analysis of the lncRNA-miRNA-mRNA Network {#s2-6}
----------------------------------------------------------

A competing endogenous RNA (ceRNA) network was constructed by the abnormal expression of lncRNAs, miRNAs and mRNAs. First, lncRNA-mRNA interactions were predicted by correlation analysis of RNA-Seq coexpression to reduce the false positives of paired lncRNA-mRNAs. The Pearson correlation coefficient was used to filter the significant paired mRNAs-lncRNAs from the RNA-Seq data. Only interactions with a Pearson correlation coefficient over 0.98 and a *P*-value \<0.01 were included. Next, lncRNA-miRNA interactions were predicted by the LncBook BIG Data Center[^3^](#fn0003){ref-type="fn"}, and miRNA-mRNA interactions were predicted by TargetScan[^4^](#fn0004){ref-type="fn"}. These predicted target genes were compared with the differentially expressed mRNAs and lncRNAs detected from RNA-Seq, and the overlapping RNAs were selected for further analysis. Then, the shared pairs from the predicted miRNA-mRNA and miRNA-lncRNA pairs potentially related to IS were selected to build the network. Finally, a miRNA-lncRNA-mRNA network potentially associated with AIS was drawn by Cytoscape based on the selected shared miRNA-lncRNA, lncRNA-mRNA and miRNA-mRNA pairs.

qRT-PCR Assay {#s2-7}
-------------

To further validate the reliability of the RNA-Seq results, quantitative real-time PCR (qRT-PCR) assays were performed. The concentration of total RNA in all samples was higher than 400 μg/μl, and the ratio of A260/280 was in the range of 1.8--2.0. Two micrograms of total RNA were reverse transcribed into cDNA using the Thermo Scientific RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, MA, USA), and RT-PCR was carried out using SYBR Premix Ex Taq (Takara, Dalian, China) according to the standard protocol. LncRNA primers were synthesized by Sangon Biotech (Shanghai, China). GAPDH was used as the internal control. The lncRNA PCR results were quantified using the 2−ΔΔCt method. All experimental reactions were performed in triplicate.

Statistical Analysis {#s2-8}
--------------------

Prior to statistical analysis, all the data were tested for normality of variance among the different groups through a Kolmogorov--Smirnov test. Comparisons of two groups of continuous variables were performed by using student's *t*-test, Wilcoxon signed-ranks or Mann--Whitney *U* tests. Statistical analyses of categorical variables were performed using the chi-square test or Fisher's exact test ([Supplementary Table S1](#SM1){ref-type="supplementary-material"}). The diagnostic performance of candidate biomarkers was analyzed by receiver operating characteristic (ROC) curves and area under curve (AUC) values. All statistical analyses were performed with GraphPad Prism 7.0 (GraphPad Software, La Jolla, CA, USA) and SPSS version 22.0 (IBM Corporation, Armonk, NY, USA). *P*-values less than 0.05 were considered statistically significant. All data are presented as the mean ± standard error of measurement (SEM). All experiments were performed in triplicate.

Results {#s3}
=======

Demographic Data of Healthy Controls and AIS Patients {#s3-1}
-----------------------------------------------------

The demographic and baseline characteristics of the 32 healthy controls and 32 patients with AIS enrolled in this study from September 2018 to June 2019 were collected. The demographic and clinical features of the participants are shown in [Table 1](#T1){ref-type="table"} ([Supplementary Table S4](#SM4){ref-type="supplementary-material"}). No significant differences in the sex, age or ethnicities or in the incidence rates of diabetes mellitus and hyperlipidemia existed between the patients with AIS and healthy controls ([Table 1](#T1){ref-type="table"}). However, the frequencies of hypertension and high homocysteine levels were significantly different between patients with AIS and healthy controls ([Table 1](#T1){ref-type="table"}, *P* \< 0.05).

###### 

Clinical characteristics of the studied subjects.

  Characteristics                    Healthy controls (*n* = 32)   AIS patients (*n* = 32)   *P*-value
  ---------------------------------- ----------------------------- ------------------------- -----------
  Age (years, mean ± SD)             63.75 ± 6.24                  64.63 ± 8.03              0.628
  Gender (male, %)                   17 (53.13%)                   18 (56.25%)               0.802
  Ethnicity (Han, %)                 32 (100%)                     32 (100%)                 1
  Hypertension (n, %)                2 (6.25%)                     25 (78.13%)               0.0001
  Diabetes mellitus (n, %)           2 (6.25%)                     3 (9.74%)                 0.64
  Hyperlipidemia (n, %)              9 (28.13%)                    12 (37.5%)                0.424
  Homocysteine (μmol/l, mean ± SD)   12.93 ± 2.79                  16.26 ± 5.34              0.02

*AIS, acute ischemic stroke; SD, standard deviation. *P* \< 0.05 was considered statistically significant. Hypertension refers to a systolic blood pressure of ≥140 mmHg or a diastolic blood pressure of ≥90 mmHg or the use of antihypertensive agents. Diabetes mellitus was defined as symptoms of diabetes and a fasting blood sugar level \>7.0 mmol/l, a random blood glucose level \>11.1 mmol/l, a 2 h post prandial blood glucose level \>11.1 mmol/l or a prior diagnosis of diabetes. Hyperlipidemia was defined as a cholesterol level \>5.72 mmol/l and/or a triglyceride level \>1.70 mmol/l or the use of antihyperlipidemic agents*.

Overview of the lncRNA and mRNA Expression Profiles in Patients With AIS and Healthy Controls {#s3-2}
---------------------------------------------------------------------------------------------

To investigate the pivotal role of lncRNAs and mRNAs that are related to the occurrence and development of AIS, RNA-Seq was carried out to detect the abnormal expression of lncRNAs and mRNAs between AIS patients and healthy controls. In total, 1,219 lncRNAs and 5,220 mRNAs were observed to be significantly differentially expressed between patients with AIS and healthy control subjects. Of those RNAs, 428 lncRNAs and 957 mRNAs were significantly upregulated, while 791 lncRNAs and 4,263 mRNAs were downregulated in patients with AIS compared with the healthy controls (*P* \< 0.05, even *q* \< 0.05 for mRNA; [Supplementary Tables S2](#SM2){ref-type="supplementary-material"}, [S3](#SM3){ref-type="supplementary-material"}).

XLOC_000410 (log2 fold change: 14.16) and XLOC_072127 (log2 fold change: −11.78) were the most upregulated and downregulated lncRNAs, respectively, in patients with AIS compared with healthy controls. Regarding mRNAs, WRNIP1 (log2 fold change: 19.26) and MKNK1 (log2 fold change: −24.93) were the most upregulated and downregulated mRNAs, respectively, in AIS patients compared with healthy controls. Detailed information, including the top 10 dysregulated (over- and underexpressed) known lncRNAs, unknown lncRNAs and mRNAs, is shown in [Tables s 2](#T2){ref-type="table"}--[4](#T4){ref-type="table"}, respectively.

###### 

Top 10 upregulated and downregulated known lncRNAs (patients with AIS vs. healthy controls).

  Transcript-id        Gene-id              Gene-name        Log2 FC   *P*-value   Up/Down
  -------------------- -------------------- ---------------- --------- ----------- ---------
  ENST00000579527.5    ENSG00000265148.5    RP5-1171I10.4    6.45      2.52E-07    up
  ENST00000644706.1    ENSG00000285498.1    CTD-2643I7.6     3.84      3.88E-05    up
  ENST00000635107.1    ENSG00000282907.1    LA16c-407A10.3   3.81      0.000246    up
  ENST00000444042.2    ENSG00000225506.2    RP1-18D14.3      3.53      0.001337    up
  ENST00000599993.5    ENSG00000268119.5    CTD-2561J22.5    3.22      0.008346    up
  ENST00000453100.1    ENSG00000224177.6    AC099344.4       3.14      0.000446    up
  ENST00000526554.1    ENSG00000255477.1    RP11-63D14.1     3.12      0.018556    up
  ENST00000540299.1    ENSG00000249790.2    RP11-20D14.6     3.00      4.69E-05    up
  ENST00000505731.5    ENSG00000249673.6    RP11-520M5.5     2.95      0.000321    up
  LENST00000585593.1   ENSG00000267122.1    AC004490.1       2.87      0.014017    up
  ENST00000419542.3    ENSG00000179818.13   AC136007.2       −10.84    3.24E-05    down
  ENST00000437964.5    ENSG00000230487.7    AC093734.11      −9.73     0.007396    down
  ENST00000620124.1    ENSG00000273951.1    RP4-620E11.8     −9.73     0.010910    down
  ENST00000527128.5    ENSG00000254876.5    RP11-23J9.5      −9.58     0.001847    down
  ENST00000623001.3    ENSG00000203875.10   SNHG5            −9.53     0.008159    down
  ENST00000612725.1    ENSG00000278740.1    RP11-147L13.14   −8.91     0.004420    down
  ENST00000609166.1    ENSG00000272979.1    RP11-647K16.1    −8.42     0.038446    down
  ENST00000502187.5    ENSG00000246223.8    C14orf64         −7.83     0.000608    down
  ENST00000581917.1    ENSG00000264895.1    RP11-421E14.2    −7.70     0.001393    down
  ENST00000623493.1    ENSG00000279059.1    RP11-257O5.2     −7.70     0.005771    down

*AIS, acute ischemic stroke; FC, fold change*.

###### 

Top 10 upregulated and downregulated unknown lncRNAs (patients with AIS vs. healthy controls).

  Transcript-id   Gene-id       Gene-name   Log2 FC   *P*-value   Up/Down
  --------------- ------------- ----------- --------- ----------- ---------
  LNC_000081      XLOC_000410   NA          14.16     6.61E-05    up
  LNC_000035      XLOC_000181   NA          12.51     3.50E-07    up
  LNC_000059      XLOC_000410   NA          12.50     0.000120    up
  LNC_000058      XLOC_000410   NA          10.22     0.000501    up
  LNC_000098      XLOC_000410   NA          10.05     7.29E-06    up
  LNC_000018      XLOC_000181   NA          8.38      0.000595    up
  LNC_003540      XLOC_100197   NA          8.31      0.000171    up
  LNC_001081      XLOC_025991   NA          8.27      0.037686    up
  LNC_002846      XLOC_079106   NA          7.23      0.00653     up
  LNC_004273      XLOC_123308   NA          7.09      0.000385    up
  LNC_002619      XLOC_072127   NA          −11.78    2.29E-05    down
  LNC_002376      XLOC_064601   NA          −9.88     0.012274    down
  LNC_001004      XLOC_024298   NA          −9.64     0.0016751   down
  LNC_002936      XLOC_081255   NA          −8.72     0.001630    down
  LNC_002114      XLOC_056683   NA          −8.33     0.000992    down
  LNC_004552      XLOC_133139   NA          −7.79     4.97E-05    down
  LNC_002926      XLOC_081252   NA          −7.76     0.003041    down
  LNC_000594      XLOC_012509   NA          −7.67     0.0012667   down
  LNC_002930      XLOC_081252   NA          −7.58     0.0261286   down
  LNC_003476      XLOC_098284   NA          −7.57     0.0027701   down

*AIS, acute ischemic stroke; FC, fold change*.

###### 

Top 10 upregulated and downregulated mRNAs (patients with AIS vs. healthy controls).

  Transcript-id     Gene-id           Gene-name   Log2.FC   *P*-value   Up/Down
  ----------------- ----------------- ----------- --------- ----------- ---------
  ENST00000380764   ENSG00000124535   WRNIP1      19.26     0.00056     up
  ENST00000409556   ENSG00000115548   KDM3A       16.86     0.00014     up
  ENST00000405977   ENSG00000132640   BTBD3       16.75     0.00166     up
  ENST00000616058   ENSG00000094975   SUCO        16.62     8.28E-12    up
  ENST00000434687   ENSG00000030419   IKZF2       15.41     0.00046     up
  ENST00000593002   ENSG00000132471   WBP2        14.70     1.69E-07    up
  ENST00000427614   ENSG00000185347   TEDC1       13.85     0.039518    up
  ENST00000620467   ENSG00000104973   MED25       13.51     8.99E-05    up
  ENST00000224756   ENSG00000107771   CCSER2      13.39     0.000136    up
  ENST00000271139   ENSG00000142961   MOB3C       13.08     0.042181    up
  ENST00000553930   ENSG00000100445   SDR39U1     12.72     0.004969    up
  ENST00000371945   ENSG00000079277   MKNK1       −24.93    9.62E-10    down
  ENST00000216780   ENSG00000100889   PCK2        −20.75    1.57E-05    down
  ENST00000574428   ENSG00000123472   ATPAF1      −20.54    0.023406    down
  ENST00000612687   ENSG00000149428   HYOU1       −19.84    1.64E-08    down
  ENST00000367446   ENSG00000116747   TROVE2      −19.41    0.022855    down
  ENST00000225430   ENSG00000108298   RPL19       −19.33    4.36E-15    down
  ENST00000628018   ENSG00000126247   CAPNS1      −18.01    0.004723    down
  ENST00000417294   ENSG00000071054   MAP4K4      −16.89    0.000334    down
  ENST00000547303   ENSG00000175197   DDIT3       −16.71    0.00664     down
  ENST00000650508   ENSG00000079277   MKNK1       −16.63    0.012937    down

*AIS, acute ischemic stroke; FC, fold change*.

The expression patterns of lncRNAs ([Figure 1A](#F1){ref-type="fig"}) and mRNAs ([Figure 1B](#F1){ref-type="fig"}) between AIS patients and healthy controls were distinguished *via* hierarchical clustering heatmaps. Red represents high relative expression, and green represents low relative expression. Volcano plots were constructed to evaluate the variation and reproducibility of lncRNA ([Figure 1C](#F1){ref-type="fig"}) and mRNA ([Figure 1D](#F1){ref-type="fig"}) expression in blood between AIS patients and healthy controls. Red circles represent upregulated genes, while green circles represent downregulated genes.

![Aberrantly expressed lncRNAs and mRNAs in patients with acute ischemic stroke (AIS) and healthy controls. Heatmap showing the hierarchical clustering of differentially expressed lncRNAs **(A)** and mRNAs **(B)** in AIS patients and healthy controls. Up- and downregulated lncRNAs and mRNAs are represented in red and green, respectively. The volcano plot of lncRNA **(C)** and mRNA **(D)** expression signals in AIS patients and healthy controls. Red circles represent upregulated genes, green circles represent downregulated genes, and the dotted line in the volcano plot represents the default significant fold change.](fnmol-12-00290-g0001){#F1}

In line with our results, mRNAs such as Bcl2 (Iwata et al., [@B25]), Bcl-W (Minami et al., [@B36]), Bcl-XL (Wiessner et al., [@B46]) and Casp3 (Gorup et al., [@B19]) and some miRNAs, such as miR-143-3p (Tiedt et al., [@B42]), miR-26b-3p (Yuan et al., [@B50]) and miR-339-5p (Dhiraj et al., [@B16]), that were previously reported to be up- or down-regulated in AIS patients were also found in this study.

Well-known lncRNAs, such as MALAT1 (Li et al., [@B29]), SNHG1 (Zhang et al., [@B51]), MIAT (Zhu et al., [@B53]) and SNHG12 (Zhao et al., [@B52]), that were previously reported as diagnostic and prognostic biomarker molecules of IS were also observed among the dysregulated lncRNAs.

GO and KEGG Pathway Analyses {#s3-3}
----------------------------

The functions and mechanisms of most lncRNAs remain elusive and may be determined from their related protein-coding genes. Therefore, we analyzed the GO and KEGG pathway enrichments of the differentially expressed mRNAs and lncRNAs between patients with AIS and healthy controls. We observed that cellular process (GO: biological process), metabolic process (GO: biological process), cell (GO: cellular component), protein binding (GO: molecular function), intracellular (GO: cellular component) and enzyme activator activity (GO: molecular function) were the most enriched terms ([Figure 2](#F2){ref-type="fig"}). The significantly enriched GO terms also included apoptotic process (GO:0006915), inflammatory response (GO:0006954), response to oxidative stress (GO:0006979), calcium-mediated signaling (GO:0019722), and response to stress (GO:0006950), which may be closely related to the pathophysiology of AIS; the detailed results are presented in [Figure 2](#F2){ref-type="fig"}. Correlation analysis of the expression levels of lncRNAs and nearby mRNAs revealed that some lncRNAs were associated with nearby mRNAs. GO enrichment and KEGG pathway analyses of these mRNAs implied that they are involved in numerous biological processes, such as apoptosis, ribosomes, the cell cycle, P53, RNA transport, vascular growth, endocytosis, oxidative response and the inflammatory response signaling pathway. Pathway analysis of the significantly differentially expressed lncRNAs related to differentially expressed mRNAs identified significantly enriched KEGG pathways ([Figure 3A](#F3){ref-type="fig"}). The significantly differentially expressed lncRNAs were enriched in pathways such as the ribosome (hsa03010), spliceosome (hsa03040), RNA transport (hsa03013), cell cycle (hsa04110), apoptosis (hsa04210), inflammatory mediator regulation of transient receptor potential (TRP) channels (hsa04750), oxidative phosphorylation (hsa00190), calcium signaling (hsa04020), p53 signaling (hsa04115) and Toll-like receptor signaling (hsa04620). Moreover, because we speculated that abnormally expressed mRNAs may also be involved in these signaling pathways, we generated a bubble diagram to identify the signaling pathways. The results showed that bubbles among the ribosome, cell cycle, P53, RNA transport, apoptosis, platelet activation, calcium, Toll-like receptor, and inflammatory signaling pathways were identified to a high degree ([Figure 3B](#F3){ref-type="fig"}). The detailed results of the pathway enrichment analysis are shown in [Figure 3](#F3){ref-type="fig"}.

![Gene ontology (GO) enrichment analysis of differentially expressed genes in AIS. **(A)** Biological process. **(B)** Cellular component. **(C)** Molecular function.](fnmol-12-00290-g0002){#F2}

![Pathway analysis of differentially expressed RNAs. **(A)** GO and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses of potential genes associated with differentially expressed lncRNAs. **(B)** GO and KEGG pathway enrichment analyses of differentially expressed mRNAs. The Rich factor represents the degree of enrichment. The node size shows the number of selected genes, and the color scale represents the --log (*P*-value).](fnmol-12-00290-g0003){#F3}

Validation of the lncRNA Expression Profile and Identification of Novel lncRNA Biomarkers for AIS {#s3-4}
-------------------------------------------------------------------------------------------------

Among the top 10 most up- and downregulated known lncRNAs, correlation analysis of RNA-Seq coexpression data between lncRNAs and nearby mRNAs demonstrated that only lncRNA-AC136007.2 and lncRNA-C14orf64 correlated with nearby mRNAs. These two lncRNAs were selected for qRT-PCR and verified in 32 AIS patients and 32 healthy controls. Both of these lncRNAs were significantly differentially expressed between AIS patients and healthy controls and demonstrated the same directional trends as those observed in the RNA-Seq data, indicating a strong consistency between the RNA-Seq data and the qRT-PCR results. The PCR results showed that lncRNA-C14orf64 and lncRNA-AC136007.2 were significantly downregulated in the circulating blood of AIS patients ([Figures 4A,B](#F4){ref-type="fig"}; [Supplementary Tables S5](#SM5){ref-type="supplementary-material"}--[S7](#SM7){ref-type="supplementary-material"}). To evaluate the potential diagnostic value of lncRNAs in AIS, we carried out ROC curve analysis to evaluate the ability of lncRNA-C14orf64 and lncRNA-AC136007.2 to distinguish patients with AIS from healthy controls. ROC curve analysis showed that the AUC values of lncRNA-C14orf64 and lncRNA-AC136007.2 between AIS patients and healthy controls were 0.74 (95% CI: 0.62--0.86, sensitivity 0.63, specificity 0.75) and 0.94 (95% CI: 0.88--0.99, sensitivity 90.63, specificity 90.63), respectively ([Figures 4C,D](#F4){ref-type="fig"}). Thus, lncRNA-C14orf64 and lncRNA-AC136007.2 were deemed considerably valuable for the diagnosis of patients with AIS. Furthermore, lncRNA-C14orf64 was predicted to target genes related to AIS, such as Bcl2, Bcl-XL, Bcl-W, BCL2L13, BCL2L14 and BCLAF1, which are critical in the apoptotic process. Based on the *P*-value, fold change, predicted target genes potentially associated with AIS, and a series of filtering pipelines, lncRNA-C14orf64 was selected for further investigation of its effects and mechanisms in AIS.

![Real-time polymerase chain reaction (RT-PCR) analysis of lncRNA expression and receiver operating characteristic (ROC) curves measuring the diagnostic efficiency of selected lncRNAs. **(A)** RT-PCR validation of the relative expression levels of lncRNA-C14orf64. **(B)** Relative expression levels of lncRNA-AC136007.2. **(C)** ROC curve for discriminating patients with AIS from healthy controls by lncRNA-C14orf64 had an area under curve (AUC) of 0.74 (95% CI, 0.62--0.86, sensitivity 0.63, specificity 0.75). **(D)** The ROC curve for discriminating patients with AIS from healthy controls *via* lncRNA-AC136007.2 had offered the greater diagnostic ability with an AUC of 0.94 (95% CI, 0.88--0.99, sensitivity 90.63, specificity 90.63). The measured RNA expression levels were normalized by GAPDH (\**P* \< 0.05, \*\**P* \< 0.001).](fnmol-12-00290-g0004){#F4}

Construction of a lncRNA-mRNA Coexpression Network {#s3-5}
--------------------------------------------------

To investigate the association between lncRNA-C14orf64 and mRNAs, a lncRNA-mRNA coexpression network was constructed based on the correlation analysis, and only the lncRNA/mRNA gene pairs with a Pearson correlation coefficient over 0.98 and a *P*-value \< 0.05 were included. Current studies have shown that IS can induce the transcription of genes related to apoptosis, the inflammatory response, oxidative stress and intracellular calcium overload (Gutiérrez et al., [@B21]). Therefore, the genes we selected were mainly enriched in pathways related to IS, such as the apoptotic process ([Figure 5A](#F5){ref-type="fig"}), inflammatory response ([Figure 5B](#F5){ref-type="fig"}), response to oxidative stress ([Figure 5C](#F5){ref-type="fig"}), and calcium-mediated signaling ([Figure 5D](#F5){ref-type="fig"}). The network of genes correlating with lncRNA-C14orf64 is shown in [Figure 5](#F5){ref-type="fig"}.

![Network of genes correlated with lncRNA-C14orf64. LncRNAs are shown as red rectangular nodes, and genes associated with apoptosis are shown as pink arrow nodes **(A)**; genes associated with the inflammatory response are shown as green triangle nodes **(B)**; genes associated with response to oxidative stress are shown as blue circular nodes **(C)**; and genes associated with calcium-mediated signaling are shown as brown square nodes **(D)**.](fnmol-12-00290-g0005){#F5}

Construction and Analysis of a lncRNA-miRNA-mRNA Network {#s3-6}
--------------------------------------------------------

Recent studies have shown that mRNAs and lncRNAs with similar sequences can be bound by the same miRNA. LncRNAs may serve as ceRNAs to sponge miRNAs, thus modulating the derepression of miRNA targets and then increasing the expression levels of mRNAs at the posttranscriptional level (Cesana et al., [@B8]). Pearson correlation coefficients estimated the complexity of interactions among genes neighboring the core gene, which were merged with miRNAs to explore lncRNA, miRNA and mRNA coexpression. Network analysis was performed to investigate which gene(s) may play a crucial role in AIS. A lncRNA-miRNA-mRNA network was constructed from predicted genes that may be associated with AIS. The lncRNA-miRNA-mRNA network indicated the relationships among lncRNAs, miRNAs and mRNAs. Bioinformatics analysis further showed that many genes (such as Bcl2, BCL2L2, BCL2L11, BCL2A1 and KDM2A), lncRNAs (C14orf64) and miRNAs (such as miR-26b-3p, miR-203a-5p, miR-339-5p, miR-3913-5p and miR-143-3p) potentially play a pivotal role in the network. The network analysis results showed that mRNAs can be coregulated by lncRNAs together with different miRNAs and that mRNAs can be coregulated by different miRNAs together with different lncRNAs. For example, KMT2A can be simultaneously regulated by miRNAs (miR-26b-3p, miR-203a-5p and miR-339-5p) and lncRNAs. The results presented here imply the potential regulatory functions of lncRNA-C14orf64 *via* interactions with specific miRNAs and mRNAs, which may play a crucial role in the pathogenesis of AIS ([Figure 6](#F6){ref-type="fig"}).

![LncRNA-miRNA-mRNA network. A ceRNA network was constructed corresponding to the miRNA, lncRNA and mRNA variations in AIS patients. Light blue oval nodes represent microRNAs, green circular nodes represent mRNAs, and red rectangular nodes represent lncRNAs. Black edges represent the possible relationship between lncRNAs and mRNAs, light blue edges represent the inhibitory effect of miRNAs on mRNAs, and red edges show the relationship between miRNAs and lncRNAs.](fnmol-12-00290-g0006){#F6}

Discussion {#s4}
==========

Given the high prevalence of IS in China, with high morbidity, mortality and disability rates, investigating the genetic mechanisms underlying AIS in the Southern Chinese Han population is very meaningful. Previous studies have demonstrated a set of peripheral blood gene expression changes specific to those with IS exhibiting brain neuronal death compared with those without neuronal death, confirming a close association between blood gene expression and brain damage (Tang et al., [@B41]). Moreover, circulating leukocytes exhibit cerebral ischemia-induced changes in the RNA expression profile detectable in circulating blood, as demonstrated in a series of animal models of IS (Tang et al., [@B40]; Sharp et al., [@B39]; Dagonnier et al., [@B13]; Li et al., [@B28]). Although emerging studies have shown that numerous lncRNAs may be involved in the regulation of IS pathophysiologic processes (Dykstra-Aiello et al., [@B17]; Wu et al., [@B49]; Zhang et al., [@B51]; Liu et al., [@B30]; Zhu et al., [@B54]), their roles in the pathological mechanisms, nosogenesis and progression of IS still need to be further clarified (Beermann et al., [@B3]). In the present study, we used high-throughput sequencing technologies to generate a signature profile of numerous lncRNAs and mRNAs in AIS compared with matched healthy controls, and bioinformatics analysis was performed to analyze the data. The RNA-Seq analysis showed that a significant number of lncRNAs and mRNAs are altered in AIS, indicating their potential regulatory functions in the pathophysiological processes of this disease.

First, we screened for genes that were differentially expressed between patients with AIS and healthy controls. The RNA-Seq data showed that 1,219 lncRNAs and 5,220 mRNAs were significantly differentially expressed between patients with AIS and healthy controls. Of these RNAs, 428 lncRNAs and 957 mRNAs were significantly increased, while 791 lncRNAs and 4,263 mRNAs were decreased. Using qRT-PCR, we selected and validated the expression of lncRNA-AC136007.2 and lncRNA-C14orf64 in AIS. The RT-PCR results showed that lncRNA-C14orf64 and lncRNA-AC136007.2 were significantly downregulated in AIS patients. The RT-PCR results were consistent with the RNA-Seq data, demonstrating that the RNA-Seq results were reliable. ROC curve analysis showed that lncRNA-AC136007.2 and lncRNA-C14orf64 can be used as potential diagnostic biomarkers of AIS. Based on a series of filtering pipelines, as mentioned above in the "Results" section, we selected lncRNA-C14orf64 for downstream experiments.

Second, we analyzed the potential functions of significantly differentially expressed lncRNAs *via* interactions with specific mRNAs. A comprehensive analysis of the differential expression pattern of lncRNAs and mRNAs will further our understanding of the biological functions of the abnormally expressed lncRNAs. Therefore, correlation analysis was conducted between the differentially expressed lncRNAs and IS-related protein-coding genes, and the correlations between the transcripts of the two groups were then identified. GO classification, coexpression and KEGG pathway enrichment analyses of the differentially expressed lncRNAs and mRNAs indicated that the apoptotic process, inflammatory response, response to oxidative stress, and calcium-mediated signaling were among the significant biological processes involved in the pathology of AIS. Among these processes, we focused on the apoptotic pathway. Our study analyzed the mRNA expression levels and observed that the expression levels of Bcl2, BCL2L2 and BCL2A1 were significantly lower in patients with AIS than in healthy controls. RNA-Seq showed that the lncRNA coding gene profile displayed concomitant downregulation of lncRNA-C14orf64 and Bcl2, BCL2L2 and BCL2A1 in the blood of AIS patients. Surprisingly, none of the top 10 most up- and downregulated lncRNAs have been related to AIS in previous studies; however, we found positive correlations between lncRNA-C14orf64, which is among the top ten most downregulated lncRNAs in AIS, and Bcl2, BCL2L2 and BCL2A1. BCL2L2 and BCL2A1 belong to the Bcl-2 protein family, the members of which are pivotal regulators of apoptosis. Bcl-2 represents the first known component of the pathophysiological cell death mechanism. Upon further investigation, researchers have found that Bcl-2 belongs to an expanding family of proteins that act as anti- and proapoptotic regulators of cell development and tissue homeostasis. Additionally, Bcl2 can block the proapoptotic actions of other members of the Bcl-2 family, such as Bad and Bax (Merry and Korsmeyer, [@B34]). The antiapoptotic function of Bcl-2 and Bcl-w is well demonstrated in models of IS, and increased expression levels of Bcl-2 and Bcl-w lead to the prevention of neuronal apoptosis by inhibiting the expression of Bax, which is a critical regulator of mitochondrial fission (Chao and Korsmeyer, [@B9]; Minami et al., [@B36]; Mikhailov et al., [@B35]; Hu et al., [@B24]).

Finally, we further explored the role of a selected lncRNA (lncRNA-C14orf64) in the pathological process of AIS by constructing a ceRNA network. Because of the complicated dynamic interaction between miRNA-mRNA pairs and miRNA-lncRNA-mRNA combinations, it is generally believed that alterations in the expression patterns of members in each group may concomitantly affect the outcome of their regulation of biological functions in various disorders (Beermann et al., [@B3]; Li et al., [@B27]; Chuang and Khorram, [@B11]). Therefore, we also constructed and analyzed the miRNA-lncRNA-mRNA network based on ceRNAs to reveal the function of lncRNA-C14orf64 in AIS. LncRNA-miRNA interactions were predicted by the LncBook BIG Data Center, revealing that lncRNA-C14orf64 potentially interacts with 82 miRNAs. Among these miRNAs, three miRNAs, miR-143-3p (Tiedt et al., [@B42]), miR-26b-3p (Yuan et al., [@B50]) and miR-339-5p (Dhiraj et al., [@B16]), were reported to be differentially expressed in IS in a previous study. Functionally, these miRNAs may potentially regulate the expression of IS-related protein-coding genes related to angiogenesis, apoptosis, inflammation, immune response, oxidative stress and atherosclerosis, which are characteristics of AIS. GO and KEGG pathway enrichment analyses of the sequencing data regarding abnormally expressed mRNAs showed that abnormally expressed transcripts in AIS are mainly involved in apoptosis, the cell cycle, the proteasome, the proinflammatory response, natural killer cell-mediated cytotoxicity, the T cell receptor signaling pathway, the NF-κB signaling pathway and RNA degradation. Our findings are consistent with the results of previous studies, which suggested that the pathogenic mechanisms underlying secondary damage at the cellular and molecular levels during AIS involve decreased antioxidant abilities and increased oxidative stress, free radical release, excitotoxicity, acute inflammatory response and apoptosis (Ritz et al., [@B38]; Cai et al., [@B6]; Hadadha et al., [@B22]).

The present study does have some limitations. First, the RNA-Seq data are limited to only a small number of samples. The PCR results were obtained from a small sample of only 32 AIS patients and 32 healthy controls, and further experimental investigation of a large sample size is necessary to assess and validate the results. Additionally, most of the conclusions of this study were generated based on only the RNA-Seq data analysis. Furthermore, we merely predicted the functions of abnormal expressed lncRNAs and were unable to validate exactly how these lncRNAs regulate target gene expression. The functional implications of the dysregulated lncRNAs await systematic investigations. In the future, we aim to further investigate and focus on the molecular mechanisms of lncRNAs in the pathological process of AIS.

Conclusion {#s5}
==========

Overall, our results provide the differential expression profile of lncRNAs in AIS in the Southern Chinese Han population with concurrent integrated expression of mRNAs and the potential regulatory functions of lncRNAs were elaborated *via* interactions with specific mRNAs which are known to be crucial in the pathological process of AIS. Further study is necessary to explore the fundamental molecular mechanisms and biological functions of lncRNAs in AIS.
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